All In Biotech

Drug Trial Radar · NCT06804096

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP): A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

129

Actual

Start

Feb 20, 2025

Primary completion

Jan 12, 2026

Study completion Jan 26, 2026

Sponsor

Lead sponsor
Dr. Md. Alimur RezaIndustry
Sponsor type
Industry
First posted
Jan 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.

Conditions

  • Pneumonia, Community-Acquired
  • Bacterial Pneumonia

Interventions

  • FaropenemDrug

    Tab. Faropenem 200mg three times daily

  • Co-amoxiclavDrug

    Tab. Co-Amoxiclav 625mg three times daily

  • Clarithromycin 500 mgDrug

    Tab. Clarithromycin 500mg two times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Cure Rate between two groups.Time frame: 10-14 days
  2. Percentage of patients withdrawn from the study due to adverse events between two groups.Time frame: 10-14 Days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Popular Medical College & Hospital

    Dhaka, Dhaka Division, Bangladesh

  • Shaheed Suhrawardy Medical College & Hospital

    Dhaka, Dhaka Division, Bangladesh

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.